Krensavage Asset Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 15, 2024), Krensavage Asset Management, LLC reported 13 stock positions worth $217.8 million. Its top holding was Exelixis (EXEL) at 17.3% of the portfolio, followed by United Therapeutics (UTHR, 17.3%) and Biogen (BIIB, 13.2%). Compared with Q1 2024, it opened 1 new position, added to 6 and reduced 5. The biggest buy was a new position in Vanda Pharmaceuticals (VNDA) and the biggest sale Cardinal Health (CAH, shares −8%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001609251
- Portfolio Value
- $217.8M (Q2 2024)
- SEC Filing
- 0001609251-24-000006 ↗ filed Aug 15, 2024
Holdings Value
Holdings 13 stocks · $217.8M
| EXEL Exelixis Inc. | 17.31% | 1,677,393 | $37.7M | Add +7.1% |
| UTHR United Therapeutics Corp. | 17.29% | 118,208 | $37.7M | Reduce -24.6% |
| BIIB Biogen Inc. | 13.18% | 123,785 | $28.7M | Reduce -7.7% |
| TARO Taro Pharmaceutical Indus | 12.83% | 650,089 | $28.0M | Add +0.3% |
| CAH Cardinal Health Inc. | 9.83% | 217,656 | $21.4M | Reduce -7.6% |
| ENTA Enanta Pharmaceuticals Inc. | 7.45% | 1,251,338 | $16.2M | Add +11.3% |
| JAZZ Jazz Pharmaceuticals PLC | 5.35% | 109,076 | $11.6M | Add +7.8% |
| BNTX Biontech SE-ADR | 4.88% | 132,293 | $10.6M | Add +10.2% |
| REGN Regeneron Pharmaceuticals | 3.79% | 7,853 | $8.3M | Reduce -37.1% |
| SNY Sanofi-ADR | 3.43% | 153,832 | $7.5M | Add +1.9% |
| ALKS Alkermes PLC | 2.85% | 257,554 | $6.2M | No change |
| VNDA Vanda Pharmaceuticals Inc. | 1.72% | 662,166 | $3.7M | New |
| MURA Mural Oncology PLC | 0.11% | 75,057 | $236K | Reduce -14.7% |
Portfolio Sells Q1 2024 → Q2 2024
Portfolio Buys Q1 2024 → Q2 2024
| VNDA Vanda Pharmaceuticals Inc. | New | 1.72% | +1.72 |
| EXEL Exelixis Inc. | Add +7.1% | 17.31% | +0.83 |
| TARO Taro Pharmaceutical Indus | Add +0.3% | 12.83% | +0.67 |
| SNY Sanofi-ADR | Add +1.9% | 3.43% | +0.17 |
| BNTX Biontech SE-ADR | Add +10.2% | 4.88% | −0.03 |
| JAZZ Jazz Pharmaceuticals PLC | Add +7.8% | 5.35% | −0.06 |
| ENTA Enanta Pharmaceuticals Inc. | Add +11.3% | 7.45% | −1.25 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 18 | $263.2M | ENTA, JAZZ, UTHR, BMRN, EXEL |
| Q1 2026 | 20 | $255.7M | UTHR, ENTA, JAZZ, BMRN, EXEL |
| Q4 2025 | 18 | $283.1M | UTHR, ENTA, BMRN, JAZZ, EXEL |
| Q3 2025 | 17 | $234.7M | UTHR, ENTA, JAZZ, BMRN, EXEL |
| Q2 2025 | 15 | $188.9M | UTHR, CAH, EXEL, JAZZ, ENTA |
| Q1 2025 | 14 | $180.9M | EXEL, UTHR, CAH, SUPN, JAZZ |
| Q4 2024Amended | 12 | $169.0M | UTHR, EXEL, CAH, BIIB, JAZZ |
| Q3 2024 | 13 | $178.5M | UTHR, EXEL, CAH, BIIB, ENTA |
| Q2 2024 | 13 | $217.8M | EXEL, UTHR, BIIB, TARO, CAH |
| Q1 2024 | 12 | $225.5M | EXEL, UTHR, BIIB, TARO, CAH |